Empagliflozin (Jardiance) is Safe in Patients with History of Limb Amputation
Empagliflozin (Jardiance) can be safely used in patients with a history of limb amputation, as multiple high-quality guidelines and clinical trials demonstrate no increased amputation risk with this specific SGLT2 inhibitor. This distinguishes empagliflozin from canagliflozin, which has shown increased amputation risk in some trials.
Evidence Supporting Safety of Empagliflozin
The most recent and authoritative guidelines explicitly differentiate between SGLT2 inhibitors regarding amputation risk:
The 2024 ACC/AHA/AACVPR Peripheral Artery Disease Guidelines 1 state that in the EMPA-REG OUTCOME trial subgroup analysis of patients with PAD at baseline (n=1,462; 20.8%), empagliflozin demonstrated superior limb survival compared to placebo. The trial showed empagliflozin reduced cardiovascular death (HR 0.57; 95% CI 0.37-0.88) without increasing amputation risk.
The 2022 Canadian Cardiovascular Society Guidelines 2 provide a strong recommendation: "Presently, there is no reason to suspect that empagliflozin or dapagliflozin increase the risk of PAD or lower limb amputations." Two large meta-analyses confirmed no overall significant increased risk of amputation with SGLT2 inhibitors as a class, with the only signal coming from canagliflozin but not empagliflozin 2.
The 2024 ESC Guidelines 3 note that in EMPA-REG OUTCOME, empagliflozin showed 5.5% amputation rate versus 6.3% with placebo (HR 0.84; 95% CI 0.54-1.32), indicating no increased risk.
The Canagliflozin Distinction
The amputation concern originated specifically with canagliflozin:
- The CANVAS trial showed canagliflozin increased amputation risk (6.3 vs 3.4 per 1,000 patient-years; p<0.001) 4
- The FDA initially added a black box warning to canagliflozin in May 2017 4
- This warning was removed in August 2020 due to conflicting subsequent data, as the CREDENCE trial did not reproduce these findings 1
Clinical Application Algorithm
For patients with history of limb amputation:
- Empagliflozin is appropriate - No increased amputation risk demonstrated
- Dapagliflozin is appropriate - No increased amputation risk demonstrated
- Canagliflozin requires caution - Mixed evidence; consider alternative SGLT2 inhibitor first
- Ertugliflozin has limited data - Minimal safety information available 4
Important Monitoring Considerations
While empagliflozin does not increase amputation risk, patients with diabetes and prior amputation remain at elevated baseline risk for limb complications. The 2018 ACC Expert Consensus 4 notes vigilance is suggested in those with history of amputation, peripheral arterial disease, neuropathy, or diabetic foot ulcers—not as a contraindication, but for appropriate monitoring.
Key monitoring points:
- Regular foot examinations for ulcers, infections, or tissue breakdown
- Assess for peripheral neuropathy and vascular disease progression
- Maintain good diabetic foot care practices 1
- Monitor for volume depletion, which could theoretically affect perfusion 5
Cardiovascular and Renal Benefits Remain
The cardiovascular benefits that make empagliflozin valuable are preserved in patients with PAD and amputation history:
- 38% reduction in cardiovascular death (HR 0.62; 95% CI 0.49-0.77) 6
- 14% reduction in MACE (HR 0.86; 95% CI 0.74-0.99) 6
- Renal protective effects 7
- Heart failure benefits 8
The FDA drug label for Jardiance 5 does not list history of amputation as a contraindication or specific warning, in contrast to the previous canagliflozin labeling. The label emphasizes monitoring for necrotizing fasciitis, genital mycotic infections, and volume depletion, but does not restrict use based on amputation history.